Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,479,331 shares of the medical equipment provider's stock after selling 338,859 shares during the quarter. Renaissance Technologies LLC owned about 1.10% of Hologic worth $178,735,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HOLX. Geode Capital Management LLC increased its position in Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after purchasing an additional 144,838 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after acquiring an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after acquiring an additional 129,035 shares in the last quarter. Invesco Ltd. raised its stake in shares of Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after acquiring an additional 572,187 shares during the period. Finally, Boston Partners lifted its holdings in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Hologic Stock Up 1.2 %

Shares of Hologic stock traded up $0.69 during trading on Friday, reaching $57.85. The company had a trading volume of 4,235,273 shares, compared to its average volume of 1,911,277. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $56.27 and a fifty-two week high of $84.67. The firm's fifty day moving average is $62.47 and its 200-day moving average is $71.49. The company has a market cap of $12.98 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the company. Stephens reissued an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Finally, William Blair reissued an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.